Tech Company Financing Transactions
Kailera Therapeutics Funding Round
On 10/14/2025, Kailera Therapeutics announced $600 million in Series B funding from Bain Capital Life Sciences and private investors.
Transaction Overview
Company Name
Announced On
10/14/2025
Transaction Type
Venture Equity
Amount
$600,000,000
Round
Series B
Investors
Bain Capital Life Sciences (Lead Investor)
Proceeds Purpose
Kailera will use the funding to run a phase 3 program for its injectable dual GLP-1/GIP receptor agonist KAI-9531.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
890 Winter Street 220
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
Advancing a broad pipeline of next-generation therapies for chronic weight management. Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions. Our experienced leadership team has a track record of building companies that deliver innovative, paradigm-shifting technologies, and is positioned to drive success, ensuring that our breakthroughs reach those who need them most.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ron Renaud
Chief Medical Officer
Scott Wasserman
Chief Operating Officer
Paul Burgess
Chief Technical Officer
Doug Bakan
VP - Human Resources
Paula Cloghessy
Browse more venture capital transactions:
Prev: 10/14/2025: Medmo venture capital transaction
Next: 10/14/2025: Patchworks venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs